Twist Bioscience Corporation (TWST) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à South San Francisco, CA, United States. Le PDG actuel est Emily Marine Leproust.
TWST a date d'introduction en bourse 2018-10-31, 923 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.52B.
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells synthetic DNA-based products using its proprietary DNA synthesis platform, which writes DNA directly onto silicon chips. The company offers a diverse portfolio including synthetic genes, sample preparation tools, antibody libraries for drug discovery, and DNA-based digital data storage solutions. Twist has established strategic collaborations with leading pharmaceutical and biotechnology firms such as Boehringer Ingelheim, Kyowa Kirin, and Centogene to advance sequencing tools and therapeutic antibody discovery. Founded in 2013 and headquartered in South San Francisco, California, the company serves the pharmaceutical, diagnostics, and data storage industries.
